Fair value seems to be around 18 - 20 cents. Company has little cash in reserve, and current pipeline has few prospects of generating much more than break-even revenue. They need to quickly in-licence a profitable drug, or face a re-rating to cash value - suggesting that a medium-term correction to 10 cents can't be ruled out.
huge market cap for specialty drug developer
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.50 |
Change
-0.490(2.45%) |
Mkt cap ! $2.492B | |||
| Open | High | Low | Value | Volume |
| $20.10 | $20.10 | $19.30 | $8.547M | 438.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $19.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.50 | 3021 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |